Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital

 总体描述(由申请人提供)：炎症性肠病研究中心(CSIBD)的总体目标是促进和促进研究，以深入了解IBD的病因和发病机制，并导致改进的治疗方法。自1991年CSIBD成立以来，这一总体目标保持不变，并指导该中心实现了实质性的增长和扩张。该研究基地由111名科学家组成，拥有4870万美元的消化系统疾病相关研究支持。将这些研究人员按重点领域组织起来，我们将CSIBD分为六个中心主题。我们理解人类IBD的目标是通过六个切入点来实现的：(1)遗传学，(2)微生物相互作用，(3)屏障功能和上皮细胞生物学，(4)先天和获得性免疫，(5)治疗学，(6)系统生物学和信号转导。每个主题都嵌入了临床医生、科学家和工程师。CSIBD的一个中心优先事项是将这些不同方法的研究人员聚集在一起，并为这些个人提供一个智力联系，以便在理解和治疗IBD方面找到共同的兴趣。这是通过几条途径实现的。首先，五个生物医学核心提供来自(1)人类遗传学和微生物组、(2)免疫学、(3)形态学和(4)遗传动物模型的领导者的最先进的资源和专业知识。除了提供指导和获取技术外，核心主任还充当调查人员之间的连接点，促进合作。同样，临床核心通过获取数以千计的患者样本来帮助社区，同时充当临床医生和基础研究人员之间互动的中心。CSIBD和布罗德研究所之间的密切关系使其能够进一步获得尖端技术，从而独立于这些核心进行运作。CSIBD的总体具体目标是：(1)促进基础科学领域的研究，以更好地了解IBD的粘膜免疫功能和上皮生物学；(2)通过将肠道作为一个“回路”来促进我们对肠道病理生理学的理解：研究决定健康和疾病的肠道细胞内和细胞间相互作用的核心成分；(3)促进IBD发病机制的研究；(4)促进科学家之间的互动，探索与IBD相关的不同领域；(5)促进翻译IBD研究；(6)吸引基础研究人员参与IBD和粘膜免疫学的研究；以及(7)提供环境和机制，促进专注于IBD的年轻研究人员的发展。一个全面的丰富计划向IBD社区介绍新成员，并鼓励来自一系列领域的研究人员之间的面对面互动。通过试点和可行性项目支持，也极大地促进了CSIBD和IBD研究吸引新成员，79%的接受者获得了外部资金，这反映了该项目的成功。

 DESCRIPTION, OVERALL (provided by applicant): The overall goal of the Center for the Study of Inflammatory Bowel Disease (CSIBD) is to promote and facilitate research that will yield insight into the causes and pathogenesis of IBD and lead to improved therapeutic approaches. This overarching objective remains unchanged since the inception of the CSIBD in 1991 and has guided the Center through substantial growth and expansion. The research base is made up of 111 scientists with $48.7 million in digestive disease-related research support. Organizing these investigators by areas of focus, we divide the CSIBD into six central themes. Our goal of understanding human IBD is accomplished using six entry points: (1) genetics, (2) microbial interactions, (3) barrier function and epithelial cell biology, (4) innate and adaptive immunity, (5) therapeutics, and (6) systems biology and signal transduction. Clinicians, scientists, and engineers are embedded in each theme. A central priority of the CSIBD is to bring together researchers from these various approaches and to provide an intellectual nexus for these individuals to find common interests in understanding and treating IBD. This is accomplished through several routes. First, the five biomedical cores offer state-of-the-art resources and expertise from leaders in (1) Human Genetics and Microbiome, (2) Immunology, (3) Morphology, and (4) Genetic Animal Models. In addition to offering guidance and access to technologies, core directors serve as connection points between investigators, facilitating collaborations. Similarly, the (5) Clinical Core aids the community through access to thousands of patient samples while serving as a hub for interactions between clinicians and basic researchers. Operating independently of these cores, the close relationship between the CSIBD and the Broad Institute allows further access to cutting-edge technologies. The overall specific aims of the CSIBD are to (1) promote research in basic science areas relevant to better understanding of mucosal immune function and epithelial biology in IBD; (2) advance our understanding of gut pathophysiology by examining the gut as a "circuit": studying the core components of gut intra- and inter-cellular interactions that determine health and disease; (3) promote the study of the pathogenesis of IBD; (4) promote interactions among scientists exploring diverse fields that share relevance to IBD; (5) promote translational IBD research; (6) attract basic investigators to the study of IBD and mucosal immunology; and (7) provide an environment and mechanism to foster development of young investigators focused on IBD. A comprehensive Enrichment Program introduces new members to the IBD community and encourages face-to-face interactions between investigators from a range of fields. Attracting new members to the CSIBD and IBD research is also greatly facilitated through Pilot and Feasibility Program support, the success of which is reflected by 79% of recipients achieving external funding.